• About
  • Board
  • News
  • Sign Up
  • Contact

Visit

VJHemOnc
Logo
  • Home (current)
  • Diseases
    ALL
    AML
    CLL
    Lymphoma
    Multiple Myeloma
    Myeloproliferative Neoplasms
    View all Diseases
  • Topics
    Measurable Residual Disease
    CAR-T & Cellular Therapy
    Pharmacy
    Nursing
    Supportive Care
    Transplantation
    View all Topics
  • Conferences
    EBMT-EHA
    CAR T-Cell Meeting
    2019
    ASH
    2018
    UKONS
    2018
    ERIC
    2018
    BOPA
    2018
    ESH MM
    2018
    View all Conferences
  • Features
  • Podcasts
    • About
    • Board
    • News
    • Sign Up
    • Contact

analysis

2:28
Midostaurin: the first drug to receive approval for AML since 2000
Arnold Ganser
1:38
Challenges with the identification of ALL subtypes
Charles Mullighan
2:24
Current understandings of ALL approaches
Charles Mullighan
1:19
Myeloma XI trial: impact of MRD on treatment response in MM
Graham Jackson
1:34
Multiple myeloma highlights at ASH 2017
Graham Jackson
2:19
ASH 2017: CLL combination therapy highlights
Arnon Kater
3:12
Results of the MURANO study for CLL
Arnon Kater
1:18
ASH 2017: combination therapy for CLL highlights
Barbara Eichhorst
1:10
Impacts of the MURANO study for future CLL treatment
Barbara Eichhorst
2:38
“Sequential triple-T” therapy for CLL
Barbara Eichhorst
2:19
Bendamustine plus rituximab vs. standard therapy for advanced CLL
Barbara Eichhorst
1:48
Novel CLL therapy highlights from ASH 2017
Anthony Mato
1:13
Checkpoint inhibitor/bispecific antibody combo: REGN2810 and REGN1979 in B-lymphoid malignancies
Anthony Mato
3:21
Triple therapy for CLL: pembrolizumab, ublituximab and umbralisib
Anthony Mato
3:36
Retrospective multicenter analysis of venetoclax-treated CLL patients
Anthony Mato
1:38
Front-line use of ibrutinib for CLL in a real-world setting
Anthony Mato
  • 1
  • 2
  • Next
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

Please enter your details if you would like to receive the latest Hemonc news and updates

Continue
Video channels
  • Acute Lymphoblastic Leukemia
  • Acute Lymphocytic Leukemia
  • Acute Myeloid Leukemia
  • Acute Promyelocytic Leukemia
  • Amyloidosis
  • Anemia
  • Aplastic Anemia
  • B-Cell Lymphoma
  • Chronic Lymphocytic Leukemia
  • Chronic Myeloid Leukemia
Join our community

Keep up-to-date via social media

Sign up for email updates

Get great new content delivered to your inbox

Sign up

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

The content of VJHemOnc is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use